Influenza vaccine and therapy
US9999662B2 · kind B2 · utility
1Cited by
13References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2014 |
| Grant date | Jun 19, 2018 |
| Priority date | — |
| Expiry date | Sep 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.